Quantcast

Latest Vancomycin Stories

2010-09-29 11:00:00

EXTON, Pa., Sept. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Jefferies 2010 Global Healthcare Conference at 10:30 A.M. ET on Wednesday, October 6, 2010. The conference is being held at the Waldorf Hilton in London. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the...

0d081dc28c1a83c830188edf659b86701
2010-09-21 10:05:00

A new study, published Tuesday in the open access journal Proteome Science, has found the presence of antibiotic-resistant enterococci bacteria in seagull stool, leading researchers to believe that the birds could be spreading difficult-to-treat infections. The team of researchers, which included Gilberto Igrejas from the University of Trás-os-Montes and Alto Douro in Portugal, studied the droppings of the Larus cachinnans species of gulls. They found that one out of every ten carry...

2010-09-21 07:00:00

SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. Optimer anticipates completing the submission in the fourth quarter of 2010 and plans to request priority review, which, if granted, could lead to an...

2010-09-15 08:00:00

EXTON, Pa., Sept. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI), a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications. VP20621 contains the spores of a naturally occurring non-toxin producing...

2010-09-14 08:30:00

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston. During an oral presentation, investigator Oliver Cornely, M.D., of the University of Cologne, presented data showing that...

2010-09-14 08:30:00

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)...

2010-09-13 12:05:38

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study. Researchers found that patients who contracted a MRSA infection with heteroresistance, called hVISA, stayed in the hospital longer, were more likely to have the infection return after 90 days, and were twice as likely to die from it after 90 days than patients who do not have hVISA. The study is being presented Sunday at the 50th annual...

2010-09-09 07:00:00

CHAPEL HILL, N.C., Sept. 9 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its oral anti-MRSA antibiotic, TAKSTA (sodium fusidate, formerly CEM-102), at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12 to 15, 2010, in Boston. Data to be presented demonstrate that TAKSTA showed clinical success rates and tolerability comparable to oral linezolid. Presentations will also provide additional data that...

2010-09-07 12:00:00

EXTON, Pa., Sept. 7 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Stifel Nicolaus 2010 Healthcare Conference at 9:10 A.M. ET on Wednesday, September 15, 2010. The conference is being held at the Four Seasons in Boston. Vincent Milano, president and chief executive officer, of ViroPharma, will present at the Fifth Annual JMP Securities Healthcare Conference...

2010-09-02 07:00:00

SAN DIEGO, Sept. 2 /PRNewswire/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo:...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related